XMEX
LABB
Market cap843mUSD
Jul 09, Last price
15.13MXN
1D
0.27%
1Q
-19.44%
Jan 2017
-29.69%
IPO
83.06%
Name
Genomma Lab Internacional SAB de CV
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genomma Lab Internacional, S.A.B. de C.V., alongside its various operating units, specializes in the creation, promotion, and distribution of a wide array of over-the-counter (OTC) pharmaceutical goods and personal care items. Its operations span across Mexico and numerous international markets. The company's extensive product portfolio addresses diverse consumer needs, encompassing categories such as skincare, hair care, general health and wellness solutions, and pain management. Specific offerings include remedies for coughs and colds, digestive health aids, sexual well-being products, antiperspirants and deodorants, hand sanitizers, isotonic beverages, and shaving essentials. Beyond these, it also markets specialized pharmaceuticals such as analgesics, antifungals, and treatments for hemorrhoids. These products are brought to market under a multitude of well-known brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Established in 1996, Genomma Lab Internacional, S.A.B. de C.V. maintains its corporate headquarters in Mexico City, Mexico.
Valuation
Title MXN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||